Illumina (ILMN) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
19 Jan, 2026Customer needs and product vision
Researchers seek faster, simpler, and more affordable sequencing workflows, with a focus on sustainability and ease of use for all experience levels.
There is demand for broader application support, reduced reagent storage needs, and lower operational costs.
MiSeq i100 Series introduction and features
MiSeq i100 Series offers same-day results, high-quality data, and streamlined, cost-efficient, sustainable operations.
The system features breakthrough simplicity, fastest runtimes, onboard DRAGEN analysis, and significant sustainability advancements.
Two configurations are available: MiSeq i100 (up to 25M reads/run) and MiSeq i100 Plus (up to 100M reads/run), both with XLEAP-SBS chemistry for improved speed and accuracy.
User experience and operational impact
Early testers report dramatically reduced turnaround times, ease of use, and room temperature reagent shipping as transformative.
Installation is quick, and the instrument is easy for technicians, with high data quality and reduced waste.
Room temperature storage eliminates thawing, enabling immediate sequencing and easier planning.
Latest events from Illumina
- Sequencing innovation, clinical growth, and end-to-end solutions drive strong outlook.ILMN
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Q4 2025 revenue up 5% to $1.16B, non-GAAP EPS up 42%, SomaLogic acquisition completed.ILMN
Q4 20255 Feb 2026 - Q2 revenue beat guidance, margins rose, but GRAIL impairments drove a $2.11B net loss.ILMN
Q2 20242 Feb 2026 - Targeting high single-digit revenue growth by 2027 through innovation and margin expansion.ILMN
Strategy Update2 Feb 2026 - Q3 2024 saw strong margins and EPS, robust NovaSeq X adoption, and the GRAIL spin-off.ILMN
Q3 202416 Jan 2026 - Strong clinical and multiomics growth, innovation, and robust financials drive future momentum.ILMN
44th Annual J.P. Morgan Healthcare Conference13 Jan 2026 - Transition to new platforms and disciplined execution support growth amid ongoing market challenges.ILMN
Wolfe Research Healthcare Conference 202413 Jan 2026 - Strong Q3 margin gains, robust sequencing demand, and X platform transition support growth targets.ILMN
7th Annual Evercore ISI HealthCONx Conference12 Jan 2026 - NovaSeq X, multiomics, and AI partnerships drive growth and margin expansion through 2027.ILMN
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026